1.Okamoto K, Yamamoto T, Nonaka D, et al.. Plasma (1—>3)-beta-D-glucan measurement and polymerase chain reaction on sputum as practical parameters in Pneumocystis carinii pneumonia. Intern Med 1998; 37(7): 618–21.
2.Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1—>3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3(2): 197–9.
3.Del BV, Mularoni A, Furfaro E, et al.. Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. CLIN VACCINE IMMUNOL 2009; 16(10): 1524–6.
4.Tasaka S, Hasegawa N, Kobayashi S, et al.. Serum indicators for the diagnosis of pneumocystis pneumonia. CHEST 2007; 131(4): 1173–80.
5.Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J INFECT CHEMOTHER 2007; 13(1): 1–7.
6.Held J, Koch MS, Reischl U, Danner T, Serr A. Serum (1—> 3)-beta-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect 2011; 17(4): 595–602.
7.Watanabe T, Yasuoka A, Tanuma J, et al.. Serum (1—>3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. CLIN INFECT DIS 2009; 49(7): 1128–31.
8.de Boer MG, Gelinck LB, van Zelst BD, et al.. beta-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect 2011; 62(1): 93–100.
9.Held J, Wagner D. beta-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2011; 17(7): 1118–22.
10.Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1—> 3)-beta-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2012; 18(5): E122–7.
11.Damiani C, Le Gal S, Da CC, et al.. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-beta-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J CLIN MICROBIOL 2013; 51(10): 3380–8.
12.Chen WZ, Pan XP and Ni ZX. Application of logistic regression model in ROC analysis. Chinese Journal of Health Statistics 2007; 24(1): 22–24.[In chinese]
13.Choi JS, Lee SH, Leem AY, et al.. Pneumocystis jirovecii pneumonia (PCP) PCR-negative conversion predicts prognosis of HIV-negative patients with PCP and acute respiratory failure. PLOS ONE 2018; 13(10).
14.Huang X, Weng L, Yi L, et al.. [Acute respiratory failure due to Pneumocystis pneumonia in connective tissue disease patients: clinical manifestation and prognostic factors related to hospital mortality]. Zhonghua Jie He He Hu Xi Za Zhi 2018; 41(3): 196–200.
15.Liu Y, Su LL, Jiang SJ, Qu H. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. ONCOTARGET 2017; 8(35): 59729–59739.
16.Li AX, Huang CY, Zhang HW, et al.. [Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia]. Zhonghua Yi Xue Za Zhi 2017; 97(11): 833–837.
17.Chen MJ, Tian XL, Qin F, et al.. Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. PLOS ONE 2015; 10(9).
18.Sage EK, Noursadeghi M, Evans HE, et al.. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. INT J STD AIDS 2010; 21(4): 288–92.
19.Ling C, Qian SY, Wang Q, et al.. Pneumocystis pneumonia in non-HIV children: a 10-year retrospective study. CLIN RESPIR J 2018; 12(1): 16–22.
20.Schmidt JJ, Lueck C, Ziesing S, et al.. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. CRIT CARE 2018; 22.
21.HARDAK E, NEUBERGER A, Yigla M, et al.. Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection. RESPIROLOGY 2012; 17(4): 681–686.
22.Roembke F, Heinzow HS, Gosseling T, et al.. Clinical outcome and predictors of survival in patients with pneumocystis jirovecii pneumonia—results of a tertiary referral centre. CLIN RESPIR J 2014; 8(1): 86–92.
23.Alvarez-Martinez MJ, Moreno A, Miro JM, et al.. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis 2008; 62(1): 34–43.
24.Aoki Y, Iwamoto M, Kamata Y, et al.. Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. RHEUMATOL INT 2009; 29(11): 1327–30.
25.Roblot F, Godet C, Le Moal G, et al.. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21(7): 523–31.
26.Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. CHEST 2005; 128(2): 573–9.
27.Asai N, Motojima S, Ohkuni Y, et al.. Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV. CHEMOTHERAPY 2017; 62(6): 343–349.
28.Tamai K, Tachikawa R, Tomii K, et al.. Prognostic value of bronchoalveolar lavage in patients with non-HIV pneumocystis pneumonia. Intern Med 2014; 53(11): 1113–7.
29.Ko Y, Jeong BH, Park HY, et al.. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J CRIT CARE 2014; 29(3): 356–361.
30.Kim SJ, Lee J, Cho YJ, et al.. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J INFECTION 2014; 69(1): 88–95.
31.Fotouhie A, Desai H, Parsa NA, King S. Gastrointestinal bleeding secondary to trimethoprim-sulfamethoxazole-induced vitamin K deficiency. BMJ Case Rep 2016; 2016.